BioPharma Resources

Drug Trial Radar · NCT02416388

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 3,100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,100

Planned (sponsor's estimate)

Start

Jan 2015

Primary completion

Jul 30, 2025

Study completion Jan 2032

Sponsor

Lead sponsor
University Hospital, AngersGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Apr 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 61 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following allogeneic SCT in first CR, after either myeloablative (MAC) or reduced intensity (RIC) conditioning, will also be evaluated. With an adaptative design, this clinical trial could test up to 3 novel AML agents of interest.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • IdarubicinDrug

    Induction chemotherapy : Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min) \+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h) Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).

  • DaunorubicinDrug

    Induction chemotherapy : Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min) \+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h) Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).

  • HD CytarabineDrug

    Consolidation chemotherapy course (s) : -High dose cytarabine: 3g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group

  • CyclosporineDrug

    GvHD prophylaxis post allogeneic SCT : -Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100

  • MethotrexateDrug

    GvHD prophylaxis post allogeneic SCT : -15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11

  • Mycophenolic acid (MPA)Drug

    GvHD prophylaxis post allogeneic SCT : * 720 mg BID from D0 to D+28 for HLA-identical siblings * 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors

  • vosaroxinDrug

    Consolidation chemotherapy course (s) : -70 mg/m² on D1 and D4

  • ID cytarabineDrug

    Consolidation chemotherapy course (s) : -Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5 For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L) Up to 3 consolidation courses, depending on the patient AML risk group

  • DexamethasoneDrug

    Consolidation chemotherapy course (s) : -10 mg/12h on D1, D3 and D5

  • VenetoclaxDrug

    Consolidation chemotherapy course (s) : Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following: * 100 mg/d on D1 to D8 (selection phase dose level 1) * or 200 mg/d on D1 to D8 (selection phase dose level 2) * or 400 mg/d on D1 to D8 (selection phase dose level 3) * or 400 mg/d on D1 to D14 (selection phase dose level 4)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: 3 years
  2. Cumulative incidence (CI) of acute Graft versus Host Disease (GvHD) of grade II to IVTime frame: 100 days
  3. Disease free survivalTime frame: 18 months

Locations

56 sites in 1 country. Site status is shown where the registry gives one.

  • CH Amiens Hôpital Sud

    Amiens, France · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • CH Victor Dupouy

    Argenteuil, France · Recruiting

  • Centre Hospitalier de la Côte Basque

    Bayonne, France · Recruiting

  • Hôpital Jean Minjoz

    Besançon, France · Recruiting

  • CH Beziers

    Béziers, France · Recruiting

  • Hôpital Avicenne

    Bobigny, France · Recruiting

  • CH Bordeaux

    Bordeaux, France · Recruiting

  • Hôpital du Dr Duchenne

    Boulogne-sur-Mer, France · Recruiting

  • Hôpital Morvan

    Brest, France · Recruiting

  • CH Caen

    Caen, France · Recruiting

  • Clinique du parc

    Castelnau-le-Lez, France · Withdrawn

  • Centre Hospitalier René Dubos

    Cergy-Pontoise, France · Recruiting

  • HIA Percy

    Clamart, France · Recruiting

  • CHU Estaing

    Clermont-Ferrand, France · Recruiting

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, France · Recruiting

  • Hôpital Henri Mondor

    Créteil, France · Recruiting

  • CHU de Dijon

    Dijon, France · Recruiting

  • CH Dunkerque

    Dunkirk, France · Recruiting

  • Hôpital Michallon

    Grenoble, France · Recruiting

  • CH Versailles

    Le Chesnay, France · Recruiting

  • CH Lens

    Lens, France · Recruiting

  • CHRU de Lille, Hôpital Huriez

    Lille, France · Recruiting

  • Hôpital St Vincent de Paul

    Lille, France · Recruiting

  • CHU de Limoges

    Limoges, France · Recruiting

  • Centre Leon Berard (CLB)

    Lyon, France · Recruiting

  • CH Lyon Sud

    Lyon, France · Recruiting

  • Marseille La Conception

    Marseille, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • CH Meaux

    Meaux, France · Recruiting

  • CHR Metz Thionville_Hôpital de Mercy

    Metz, France · Recruiting

  • Hôpital Saint Eloi

    Montpellier, France · Recruiting

  • CH Mulhouse

    Mulhouse, France · Recruiting

  • CH Hôtel Dieu

    Nantes, France · Recruiting

  • Centre Antoine Lacassagne

    Nice, France · Recruiting

  • CHU Nice

    Nice, France · Recruiting

  • CHRU de Nîmes

    Nîmes, France · Recruiting

  • Hôpital Cochin

    Paris, France · Recruiting

  • Hôpital La Pitié Salpêtrière

    Paris, France · Recruiting

  • Hôpital Necker Enfants Malades

    Paris, France · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.